BiomedAI, Inc. is an AI-driven drug development company founded on Dr. Lloyd Tran’s Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases. The company seeks to transform medicine by combining artificial intelligence, systems biology, and translational therapeutics to address the underlying causes of chronic diseases.
The Unified Theory proposes that conditions such as Alzheimer’s disease, obesity, diabetes, and cardiovascular disease are not isolated disorders but interconnected manifestations of shared biological dysfunctions.
Using AI, multi-omics data integration, predictive modeling, and therapeutic discovery platforms, BiomedAI aims to uncover common disease pathways, identify novel biomarkers, develop multi-target treatments, and advance precision medicine solutions that improve health outcomes worldwide.
BIOMARKER DISCOVERY
BiomedAI has established an integrated biomarker discovery initiative using AI to identify molecular signatures predictive of disease progression across interconnected chronic diseases.
AI models will analyze large-scale datasets to identify combinations of biomarkers capable of predicting disease years before clinical symptoms emerge.
BiomedAI has developed Unified Acceleration Platform™ for Biomed Industries, Inc.
Rather than targeting symptoms within individual organs, the Platform embraces the paradigm that chronic diseases stem from system-wide dysregulation. This insight guides the rapid development of therapeutics that modulate upstream biological processes, accelerating translational research and drug development beyond traditional disease silos.
Thanks to the contribution of BiomedAI, Biomed Industries, Inc has developed a family of patented drugs for the treatment of ALS, Alzheimer’s disease, major depressive disorder, stroke, diabetes obesity, MASH and rare diseases including Rett Syndrome and Fragile X.
